Bafna Pharmaceuticals Ltd approves unaudited Q2 and H1 FY27 results, reporting Q2 revenue of ₹47.67 crore and net profit of ₹6.85 crore
- Q2 revenue rose 79.3% sequentially and 34.4% year on year.
- Net profit increased from ₹7.51 lakh in Q1 FY27 and ₹312.49 lakh in Q2 FY26.
- Auditor issued an unmodified limited-review conclusion, with an emphasis of matter on GST claims and related legal proceedings; management does not expect an adverse financial outcome.
